Multiple Sclerosis Clinical Trial
Official title:
A Randomized, Placebo-Controlled Study of Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis
Purpose To determine whether Mindfulness-Based Treatment for Insomnia (MBTI) is more
effective in the treatment of chronic insomnia disorder (CID) in patients with multiple
sclerosis (MS) when compared with standard sleep hygiene counseling.
Specific Aims / Hypotheses
Our specific aims are to determine:
- Whether MBTI is more effective than standard sleep hygiene counseling in improving
objectively-measured sleep quality among this group of MS patients with CID, as measured
by the Fitbit Charge 2 activity tracker.
- Whether MBTI is more effective than standard sleep hygiene counseling in improving
self-reported sleep quality among this group of MS patients with CID, as measured by the
Pittsburgh Sleep Quality Index (PSQI).
- Whether MTBI is more effective than standard sleep hygiene counseling in reducing
self-reported severity of insomnia among this group of MS patients with CID, as measured
by the Insomnia Severity Index (ISI).
- Whether MBTI is more effective than standard sleep hygiene counseling in improving
self-reported quality of life among this group of MS patients with CID, as measured by
the Multiple Sclerosis Quality of Life Inventory (MSQLI).
We hypothesize that among study participants with MS and CID:
- MBTI will improve their objectively-measured sleep quality, as measured by the Fitbit
Charge 2 activity tracker.
- MBTI will improve their self-reported sleep quality, as measured by the PSQI.
- MBTI will reduce their self-reported severity of insomnia, as measured by the ISI.
- Improvement in sleep quality and reduction in insomnia severity will result in
improvement in self-reported quality of life, as measured by MSQLI scores.
- MBTI will be superior to sleep hygiene counseling in improving sleep quality, reducing
insomnia severity, and improving quality of life.
BACKGROUND:
An estimated 25 to 40 percent of individuals with multiple sclerosis (MS) suffer from chronic
insomnia, and the prevalence of sleep disorders is often unrecognized. Chronic insomnia
disorder (CID) is defined as persistent difficulty with sleep initiation, duration,
consolidation, or quality that occurs despite adequate opportunity and circumstances for
sleep, leading to daytime impairment, and ongoing for at least three consecutive months.
Common causes of CID in MS include motor disorders such as cramps, spasms, restless leg
syndrome and periodic limb movements, neuropathic pain, bladder dysfunction (such as
nocturia), and obstructive sleep apnea. Depression, anxiety, daytime fatigue, and cognitive
dysfunction are also associated with sleep disorders in MS. Moreover, treatments for the
underlying disease, such as interferon therapy, as well as treatments for various symptoms of
MS, such as stimulant medications used to treat fatigue, may also contribute to insomnia.
Many patients manage their insomnia using benzodiazepines and other medications, which may be
associated with a number of adverse effects, including dependence and tolerance, cognitive
dysfunction, and depression. Furthermore, other adverse effects of benzodiazepines arise from
their use in combination with other drugs such as opioid narcotics for pain. Therefore, it is
desirable to find effective nonpharmacological treatments for insomnia in patients with
multiple sclerosis.
Psychologically-based and behavioral treatments have been widely tested in various cohorts of
patients with CID with and without co-morbid conditions. These methods include cognitive
behavioral therapies (CBT), sleep hygiene programs, mindfulness meditation, and others. In a
randomized controlled clinical trial of 72 women with CID and MS in Iran, CBT treatment was
associated with improved sleep quality as measured by the Pittsburgh Sleep Quality Index
(PSQI). A case series of 11 patients with chronic insomnia and MS who were treated with CBT
at the Cleveland Clinic Sleep Disorders Center improved on measures of insomnia, fatigue and
depression, as well as an increase in total sleep time of 1.5 hours.
Mindfulness based stress reduction (MBSR) is an empirically-supported intervention designed
to decrease stress, chronic and acute pain and anxiety in adults. Mindfulness is the practice
of focusing full attention on the present moment intentionally and without judgment. The
practice of mindfulness is hypothesized to reduce feelings of distress and stress reactivity
by increasing one's awareness of and ability to tolerate thoughts and emotions. Mindfulness
may help individuals decrease distress and over-reactivity to events and increase the ability
to respond to events in ways that one consciously chooses (rather than through automatic
'mindless" behaviors). Mindfulness-based interventions such as MBSR teach mindfulness through
meditation, yoga, present-minded awareness in everyday life, and discussions of stress
physiology and coping.
Several studies have demonstrated the effectiveness of MBSR interventions in the treatment of
insomnia. Long-term meditators have been shown to have increased parietal-occipital gamma
(25-40 Hz) during NREM (non-rapid eye movement sleep), showing that MBSR can induce objective
changes in sleep architecture. MBSR and MBTI (mindfulness based treatment of insomnia) have
been shown in randomized, controlled studies to decrease sleep latency and total waking time
and increase sleep time.These effects, moreover, have been durable. However, a meta-analysis
of 6 randomized controlled trials involving 330 participants showed that mindfulness
meditation significantly improved total wake time and sleep quality, but had no significant
effects on sleep onset latency, total sleep time, wake after sleep onset, sleep efficiency,
total wake time, Insomnia Severity Index (ISI), PSQI, or Dysfunctional Beliefs and Attitudes
Sleep Scale (DBAS).
Mindfulness training has been shown to be beneficial in improving several symptoms of MS,
including those that have been shown to impact sleep. A randomized, controlled study of 150
patients undergoing mindfulness training showed improvements in quality of life and
well-being, including fatigue and depression. Furthermore, there is Class 1 evidence that
stress reduction in MS can affect the underlying inflammatory biology of MS, as evidenced by
a reduction in new MRI lesions. However, many other studies showing benefits of stress
reduction in MS are limited by their descriptive nature and non-controlled design.
The significance of this study is that while there are data showing the effectiveness of
mindfulness-based techniques in treating insomnia in general, and some data showing the
benefits of using non-mindfulness stress reduction techniques in the management of MS-related
insomnia, there have been no studies to date on the efficacy of mindfulness techniques in
treating MS-related insomnia.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|